HR-Positive, HER2-Negative Breast Cancer Specialty Channel

HR+/HER2– Breast Cancer

Specialty Channel

News

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer

10/29/2024

Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.

Primary results from the...

10/29/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...

Landmark 4-year analysis results...

10/04/2024

Oncology

News

First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

07/11/2024

Stephanie Holland ;

Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...

Results from the phase 2 RIGHT...

07/11/2024

Oncology

Kevin Kalinsky, MD, Winship Cancer Institute

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Conference Coverage

Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/06/2024

Allison Casey ;

According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.

According to results from a...

06/06/2024

Oncology

News

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer

10/29/2024

Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.

Primary results from the...

10/29/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results...

10/04/2024

Oncology

News

First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

07/11/2024

Stephanie Holland ;

Results from the phase 2 RIGHT...

07/11/2024

Oncology

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Conference Coverage

Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/06/2024

Allison Casey ;

According to results from a...

06/06/2024

Oncology

Recent News

News

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer

10/29/2024

Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.

Primary results from the...

10/29/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results...

10/04/2024

Oncology

News

First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

07/11/2024

Stephanie Holland ;

Results from the phase 2 RIGHT...

07/11/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology